Krystal Biotech, Inc.
KRYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United. With a market capitalization of $8.79B, it sits in mid-cap territory. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Market Cap
$8.79B
Beta
0.49
P/E (TTM)
39.85
P/E (Fwd)
29.57
EPS (TTM)
$7.48
EPS (Fwd)
$10.08
ROE
19.9%
ROA
9.0%
Cash
$823.4M
Total Debt
$9.1M
Free CF
$137.5M
52W Change
127.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $823.4M in cash comfortably exceeding the $9.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $137.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 19.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.0% suggests reasonable efficiency in deploying the company's asset base.
KRYS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Krystal Biotech, Inc. and its sector.